Overview

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
A Randomized Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Aligos Therapeutics